How psychotropic polypharmacy in schizophrenia begins: A longitudinal perspective

Pharmacopsychiatry

Volumn 45, Issue 4, 2012, Pages 133-137

  Shinfuku, M ^a,b   Uchida, H ^a,c,d   Tsutsumi, C ^a,e   Suzuki, T ^a   Watanabe, K ^a,f   Kimura, Y ^d,f   Tsutsumi, Y ^g   Ishii, K ^f   Imasaka, Y ^f,h   Mimura, M ^a   Kapur, S ⁱ  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Asaka Hospital   (Japan)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d Asakadai Mental Clinic   (Japan)

^e Komagino Hospital   (Japan)

^f Ohizumi Hospital   (Japan)

^g Ongata Hospital   (Japan)

^h Ohizumi Mental Clinic   (Japan)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

concomitant drugs; polypharmacy; psychotropics; schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ALGORITHM; ARTICLE; CLINICAL PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYPHARMACY; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862567283     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1297934     Document Type: Article

References (37)

1. Chakos M H, Glick I D, Miller A L et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv: 2006; 57 1094 1101 (Pubitemid 44204901)
2. Magliano L, Fiorillo A, Guarneri M et al. Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey. Eur J Clin Pharmacol: 2004; 60 513 522 (Pubitemid 39350164)
3. Fourrier A, Gasquet I, Allicar M P et al. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol: 2000; 49 80 86 (Pubitemid 30050490)
4. McCue R E, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry: 2003; 64 984 989 (Pubitemid 37158242)
5. Acquaviva E, Gasquet I, Falissard B. Psychotropic combination in schizophrenia. Eur J Clin Pharmacol: 2005; 61 855 861 (Pubitemid 41720275)
6. Mallinger J B, Lamberti S J. Racial differences in the use of adjunctive psychotropic medications for patients with schizophrenia. J Ment Health Policy Econ: 2007; 10 15 22 (Pubitemid 46605737)
7. Lehman A F, Lieberman J A, Dixon L B et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry: 2004; 161 1 56
8. Buchanan R W, Kreyenbuhl J, Kelly D L et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull: 2010; 36 71 93
9. Tsutsumi C, Uchida H, Suzuki T et al. The evolution of antipsychotic switch and polypharmacy in natural practice - A longitudinal perspective. Schizophr Res: 2011; 130 40 46
10. Vares M, Saetre P, Stralin P et al. Concomitant medication of psychoses in a lifetime perspective. Hum Psychopharmacol June 22: 2011; 10.1002/hup.1209 [E-pub ahead of print]
11. World Health Organization The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. World Health Organization Geneva: 1992
12. Haahr U, Friis S, Larsen T K et al. First-episode psychosis: diagnostic stability over one and two years. Psychopathology: 2008; 41 322 329
13. Schwartz J E, Fennig S, Tanenberg-Karant M et al. Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. Arch Gen Psychiatry: 2000; 57 593 600 (Pubitemid 30349440)
14. Gelenberg A J, Van Putten T, Lavori P W et al. Anticholinergic effects on memory: benztropine versus amantadine. J Clin Psychopharmacol: 1989; 9 180 185 (Pubitemid 19155158)
15. Mamo D C, Sweet R A, Keshavan M S. Managing antipsychotic-induced parkinsonism. Drug Saf: 1999; 20 269 275 (Pubitemid 29134900)
16. Monane M, Avorn J, Beers M H et al. Anticholinergic drug use and bowel function in nursing home patients. Arch Intern Med: 1993; 153 633 638 (Pubitemid 23072392)
17. Anonymous Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. World Health Organization heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness. Br J Psychiatry: 1990; 156 412
18. Heinik J. Effects of trihexyphenidyl on MMSE and CAMCOG scores of medicated elderly patients with schizophrenia. Int Psychogeriatr: 1998; 10 103 108 (Pubitemid 28284564)
19. Bottiggi K A, Salazar J C, Yu L et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry: 2006; 14 980 984 (Pubitemid 44706417)
20. Kay G G, Abou-Donia M B, Messer W S Jr. et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc: 2005; 53 2195 2201 (Pubitemid 43001205)
21. Uchida H, Mamo D C, Mulsant B H et al. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry: 2009; 70 397 405
22. Singh M M, Kay S R. Therapeutic reversal with benxtropine in schizophrenics. Practical and theoretical significance. J Nerv Ment Dis: 1975; 160 258 266
23. Johnstone E C, Crow T J, Ferrier I N et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med: 1983; 13 513 527 (Pubitemid 13019017)
24. Tonda M E, Guthrie S K. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy: 1994; 14 543 560 (Pubitemid 24299954)
25. Volz A, Khorsand V, Gillies D et al. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2007; CD006391 10.1002/14651858.CD006391 (Pubitemid 351835435)
26. Swift C G, Swift M R, Hamley J et al. Side-effect tolerance' in elderly long-term recipients of benzodiazepine hypnotics. Age Ageing: 1984; 13 335 343 (Pubitemid 15205673)
27. Angus W R, Romney D M. The effect of diazepam on patients' memory. J Clin Psychopharmacol: 1984; 4 203 206 (Pubitemid 14061178)
28. Nurmi-Luthje I, Kaukonen J P, Luthje P et al. Use of benzodiazepines and benzodiazepine-related drugs among 223 patients with an acute hip fracture in Finland: Comparison of benzodiazepine findings in medical records and laboratory assays. Drugs Aging: 2006; 23 27 37 (Pubitemid 43290882)
29. Xiang Y T, Weng Y Z, Leung C M et al. Clinical and social determinants of long-term use of benzodiazepines and its impact on quality of life of Chinese schizophrenia patients. Pharmacopsychiatry: 2007; 40 269 274
30. Nutt D J, Wilson S. Evaluation of severe insomnia in the general population - implications for the management of insomnia: the UK perspective. J Psychopharmacol: 1999; 13 S33 S34 (Pubitemid 30055126)
31. Moller HJ. Effectiveness and safety of benzodiazepines. J Clin Psychopharmacol: 1999; 19 2S 11S
32. Nakajima S, Uchida H, Suzuki T et al. An open-label trial of discontinuing benzodiazepines in patients with chronic schizophrenia. J Clin Psychopharmacol: 2007; 27 401 403 (Pubitemid 47075516)
33. Tsunoda K, Uchida H, Suzuki T et al. Effects of discontinuing benzodiazepine-derivative hypnotics on postural sway and cognitive functions in the elderly. Int J Geriatr Psychiatry: 2010; 25 1259 1265
34. Suzuki T, Uchida H, Takeuchi H et al. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Human Psychopharmacol: 2009; 24 628 638
35. Uchida H, Suzuki T, Mamo D C et al. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry: 2008; 16 584 593
36. Uchida H, Suzuki T, Mamo D C et al. Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan. J Anxiety Disord: 2009; 23 477 481
37. Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev: 2006; 3 CD005581 10.1002/14651858.CD005581.pub2